Emergency Trends In Clinical Diagnostics Will Helping To Grow Cardiac Biomarkers Market Till 2024:Grand View Research,Inc.
The cardiac biomarkers market is expected to reach
USD13.3 billion by 2024, according to a new report by Grand View Research, Inc.
The cardiac biomarkers market is anticipated to witness a lucrative growth
during the forecast period from 2016 to 2024. Analysis of global market trends
focuses on the increasing demand for cardiac biomarkers owing to its increased
adoption in cardiovascular disease diagnosis. Furthermore, this growth is
attributed to a majority of factors, such as the high prevalence of Acute
Coronary Syndrome (ACS), continual technological advancements in the development
of cardiovascular biomarkers, increasing number of new product launches by the
key market players, rising demand for point of care cardiac testing kits, along
with the high specificity and sensitivity of these biomarkers in the detection
of cardiovascular diseases, especially acute myocardial infarction.
The cardiac biomarkers market has
been classified by type into troponin, Creatine kinase-MB(CK-MB), B-type
Natriuretic Peptide (BNP), and N-terminal pro b-type natriuretic peptide
(NT-proBNP), myoglobin, and others. Troponin is a heteromeric protein and
comprises cardiac troponin T & I, which are abbreviated as cTnT & cTnI,
respectively. The troponin biomarkers segment is expected to grow lucratively
in the forecast period at a significant CAGR. The diagnostic efficiency and
specificity related to cardiac biomarker testing renders it a universally gold
standard test to diagnose cardiovascular disorders worldwide. The market by
application is segmented into acute coronary syndrome, myocardial infarction,
congestive heart failure, and others. ACS is expected to be the highest
grossing segment according to the study. ACS is responsible for huge medical
costs globally and is responsible for most hospital readmission cases. The
increasing efforts to cut down worldwide ACS prevalence rates are expected to
drive the growth of the biomarkers market.
The key countries included in the
report are U.S., Canada, Germany, UK, China, India, Brazil, Mexico, South
Africa, and the Middle East. North America accounted for the largest market in
2015, whereas the Asia Pacific region is anticipated to be the fastest growing
region during the forecast period.
Browse full research report on Cardiac
Biomarkers Market Analysis:
Further key findings from the report suggest:
- North America
is estimated to dominate the global cardiac biomarkers market. The high
prevalence of coronary heart disease in western countries is one of the
major factors contributing to the high demand for cardiac biomarker
diagnostics.
- The Asia
Pacific region is anticipated to be the fastest growing region in the
study period owing to the large population, especially in China and India.
Apart from that, there exists a high prevalence rate of myocardial
infarction in the region. This prevalence rate is expected to fuel the
demand for cardiac biomarker diagnostics.
- The troponin
biomarker segment is expected to grow at a significant rate, and is
expected to grow at the highest CAGR compared to others and accounts for
the largest market share in 2015.
- The sector
comprises of several local as well as global players. Some of the major players
of this vertical include Alere, Inc., Siemens Healthcare GmbH, Roche
Diagnostics, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc.,
Becton, Dickinson and Company, and bioMerieux SA.
For more information: http://www.grandviewresearch.com
Comments
Post a Comment